We are live on ! Find out more
JSPR icon

Jasper Therapeutics

53 hedge funds and large institutions have $35.2M invested in Jasper Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 10 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

570% more call options, than puts

Call options by funds: $449K | Put options by funds: $67K

100% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 10

3.34% less ownership

Funds ownership: 72.03% → 68.69% (-3.3%)

7% less funds holding

Funds holding: 57 → 53 (-4)

11% less capital inflows, than outflows

Capital inflows: $11.7M | Capital outflows: $13.1M

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
53
Holders Change
-4
Holders Change %
-7.02%
% of All Funds
0.64%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
12
Increased
20
Reduced
10
Closed
15
Calls
$449​K
Puts
$67​K
Net Calls
+$382​K
Net Calls Change
+$192​K

JSPR Hedge Fund Activity: Q4 2025 in Review

53 of the 8,319 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2025, worth a combined $35.2M — down 26% from $47.8M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of JSPR and 12 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 20 added.

The largest buyer was Goldman Sachs, adding an estimated $3.45M. The largest seller was Kingdon Capital Management, exiting entirely with an estimated $3.15M sold.

  • 53 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2025, down from 57 in Q3 2025.
  • Funds reported $35.2M of Jasper Therapeutics stock for Q4 2025, down 26% quarter-over-quarter.
  • 12 funds opened new Jasper Therapeutics positions in Q4 2025 and 15 closed out, a net change of -3 holders.
  • The largest Jasper Therapeutics buyer in Q4 2025 was Goldman Sachs, an estimated $3.45M added.
  • The largest Jasper Therapeutics seller in Q4 2025 was Kingdon Capital Management, an estimated $3.15M sold.

Based on aggregated 13F filings for Q4 2025.